The American Journal of Managed Care
This supplement to provides participants with a review of human papillomavirus vaccination. This supplement has been reviewed by an expert in the field.
Faculty
Matthew M. Davis, MD, MAPP
Internal Medicine, and Public Policy
C.S. Mott Children's Hospital
Ann Arbor, Michigan
Amanda F. Dempsey, MD, PhD, MPH
Child Health Evaluation and Research (CHEAR) Unit
University of Michigan
Professor of Epidemiology and Oncology
Department of Oncology
Montreal, Quebec, Canada
Pamela Ann Hymel, MD, MPH
Medical Director
San Jose, California
Helen Trottier, PhD, MSc
Division of Cancer Epidemiology
McGill University
Disclosure Statement
In accordance with the ACCME and the ACPE, participants for this activity have completed conflict- of-interest statements.
In compliance with the Health Insurance Portability and Accountability Act standards, no presentations in this CME/CE activity shall disclose the names or other identifiers of patients referenced without a signed waiver from the identified patient.
The American Journal of Managed Care
It is the policy of to have all faculty who participate in programs sponsored by corporate organizations disclose any real or apparent conflicts of interest.
These participants report relationships with the following pharmaceutical companies:
Grant support from:
Eduardo L. Franco, DrPH, MPH
Consultant fees from:
The following participants have declared no financial affiliations with corporate organizations:
Investigational and/or Off-label Use of Commercial Products and Devices
The University of Cincinnati College of Medicine requires all faculty to disclose any discussion of investigational and/or off-label use of a pharmaceutical product or device within their presentation. Participants should note that the use of products outside US Food and Drug Administration-approved labeling should be considered experimental and are advised to consult current prescribing information for approved indications.
The faculty claim not to discuss any investigational and/or off-label use of a pharmaceutical product or device.
The American Journal of Managed Care
Signed disclosures are on file at the office of , Princeton, New Jersey.
Editor's note: Mention of trade names and particular pharmaceutical companies in this supplement is for the reader's reference only. Promoting any pharmaceutical company or its commerical interests should not be inferred.
GOAL
To increase understanding of the etiologic role of human papillomavirus (HPV) in development of cervical cancer and other diseases, the potential for HPV vaccination to reduce the risk of these clinical sequelae, and the burden on the healthcare system.
TARGET AUDIENCE
This activity is intended for physicians, medical directors, pharmacists, pharmacy directors, primary care physicians, and other managed care decision makers.
LEARNING OBJECTIVES
After completing this continuing education activity, the participant should be able to:
CONTINUING MEDICAL EDUCATION ACCREDITATION
AMA
PRA Category 1 CME credit(s)
.
The University of Cincinnati College of Medicine designates this educational activity for a maximum of two (2) â„¢Physicians should only claim credit commensurate with the extent of their participation in this activity.
The University of Cincinnati College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor medical education for physicians.
Release Date: December 1, 2006. Expiration Date: December 1, 2007.
CONTINUING PHARMACY EDUCATION ACCREDITATION
Pharmacy Times
/Ascend Media Office of Continuing Professional Education is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This program is approved for 2 contact hours (0.2 CEUs) under the ACPE universal program number of 290-999-06-018-H01.
Release Date: December 1, 2006. Expiration Date: December 1, 2007.
FUNDING
This program is supported by an educational grant from GlaxoSmithKline.
---
The contents of this supplement may include information regarding the use of products that may be inconsistent outside the approved labeling for these products in the United States. Physicians should note that the use of these products outside current approved labeling is considered experimental and are advised to consult prescribing information for these products.